# A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

> **NCT07340190** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** pelabresib
- **DRUG:** repaglinide
- **DRUG:** midazolam
- **DRUG:** drospirenone
- **DRUG:** ethinyl estradiol

## Key facts

- **NCT ID:** NCT07340190
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2028-03-09
- **Final completion:** 2028-04-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07340190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07340190, "A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07340190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*